Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

NCT01014091 PHASE3 TERMINATED Results posted

The objective of this study is to evaluate the safety and immunogenicity study of GSK Biologicals' pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	TERMINATED
Enrolment	60
Start date	Tue Dec 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 14 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza

Interventions

• GSK pandemic vaccine GSK2340272A

Countries

Czechia